Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Costa Clemens SA. et al, (2023), Hum Vaccin Immunother, 19
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157
A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.
Rajan M. et al, (2022), The Pediatric infectious disease journal, 42, 66 - 73
Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer: Randomized clinical trial
Hill J. et al, (2022), British Journal of Surgery, 109, 1073 - 1080
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
Marchevsky NG. et al, (2022), EBioMedicine, 81
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G. et al, (2022), Lancet, 399, 2212 - 2225
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Ogbe A. et al, (2022), JCI Insight, 7
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Clemens SAC. et al, (2021), Nature Communications, 12
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Clemens SAC. et al, (2021), Nat Commun, 12
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Barrett JR. et al, (2021), Nature medicine
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR. et al, (2021), Nature medicine
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M. et al, (2021), Lancet, 397, 881 - 891
Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.
Bach SP. et al, (2021), Lancet Gastroenterol Hepatol, 6, 92 - 105